Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

HIV controllers: to treat or not to treat? Is that the right question?

Noël N, Saez-Cirion A, Avettand-Fenoël V, Boufassa F, Lambotte O.

Lancet HIV. 2019 Oct 14. pii: S2352-3018(19)30264-4. doi: 10.1016/S2352-3018(19)30264-4. [Epub ahead of print] Review.

PMID:
31624011
2.

False-negative Results of Human Immunodeficiency Virus (HIV) Rapid Testing in HIV Controllers.

Hage-Sleiman M, Tremeaux P, Fillion M, Boufassa F, Melard A, Gardiennet E, Mariaggi AA, Plantier JC, Rouzioux C, Lambotte O, Avettand-Fenoel V; CODEX ANRS Cohort Study Group .

Clin Infect Dis. 2019 Sep 21. pii: ciz734. doi: 10.1093/cid/ciz734. [Epub ahead of print]

PMID:
31541253
3.

The proportion of CD57+ cells among effector CD8+ T cells is lower HIV controllers compared to ART treated patients.

Henriquez S, Lecuroux C, Bitu M, Avettand-Fenoel V, Churaqui F, Catalan P, Cheret A, Boufassa F, Saez-Cirion A, Monceaux V, Meyer L, Goujard C, Lambotte O, Bourgeois C; ANRS CO6 PRIMO, the ANRS CO21 CODEX cohorts.

AIDS. 2019 Aug 2. doi: 10.1097/QAD.0000000000002342. [Epub ahead of print]

PMID:
31385864
4.

Cardiovascular Events in the French ANRS HIV Controller Cohort.

Noël N, Gominet M, Meyer L, Boufassa F, Lambotte O.

J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):e32-e34. doi: 10.1097/QAI.0000000000002108. No abstract available.

PMID:
31192824
5.

Increasing contribution of integrated forms to total HIV DNA in blood during HIV disease progression from primary infection.

Trémeaux P, Lenfant T, Boufassa F, Essat A, Mélard A, Gousset M, Delelis O, Viard JP, Bary M, Goujard C, Rouzioux C, Meyer L, Avettand-Fenoel V; ANRS-SEROCO and PRIMO cohorts.

EBioMedicine. 2019 Mar;41:455-464. doi: 10.1016/j.ebiom.2019.02.016. Epub 2019 Feb 23.

6.

Dynamics in HIV-DNA levels over time in HIV controllers.

Avettand-Fenoel V, Bayan T, Gardiennet E, Boufassa F, Lopez P, Lecuroux C, Noel N, Trémeaux P, Monceaux V, Autran B, Meyer L, Saez-Cirion A, Lambotte O, Rouzioux C; CODEX ANRS Cohort Study Group.

J Int AIDS Soc. 2019 Jan;22(1):e25221. doi: 10.1002/jia2.25221.

7.

Cellular Metabolism Is a Major Determinant of HIV-1 Reservoir Seeding in CD4+ T Cells and Offers an Opportunity to Tackle Infection.

Valle-Casuso JC, Angin M, Volant S, Passaes C, Monceaux V, Mikhailova A, Bourdic K, Avettand-Fenoel V, Boufassa F, Sitbon M, Lambotte O, Thoulouze MI, Müller-Trutwin M, Chomont N, Sáez-Cirión A.

Cell Metab. 2019 Mar 5;29(3):611-626.e5. doi: 10.1016/j.cmet.2018.11.015. Epub 2018 Dec 20.

PMID:
30581119
8.

Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors.

Shaiykova A, Pasquet A, Goujard C, Lion G, Durand E, Bayan T, Lachâtre M, Choisy P, Ajana F, Bourdic K, Viget N, Riff B, Quertainmont Y, Cortet B, Boufassa F, Chéret A.

AIDS. 2018 Nov 28;32(18):2689-2696. doi: 10.1097/QAD.0000000000002001.

PMID:
30234605
9.

Does Quality of Life and Sexual Quality of Life in HIV Patients Differ Between Non-treated HIV Controllers and Treated Patients in the French ANRS VESPA 2 National Survey?

Préau M, Mora M, Puppo C, Laguette V, Sagaon-Teyssier L, Boufassa F, Meyer L, Lambotte O, Spire B.

AIDS Behav. 2019 Jan;23(1):132-139. doi: 10.1007/s10461-018-2237-8.

PMID:
30073634
10.

Systemic DPP4 activity is reduced during primary HIV-1 infection and is associated with intestinal RORC+ CD4+ cell levels: a surrogate marker candidate of HIV-induced intestinal damage.

Ploquin MJ, Casrouge A, Madec Y, Noël N, Jacquelin B, Huot N, Duffy D, Jochems SP, Micci L, Lécuroux C, Boufassa F, Booiman T, Garcia-Tellez T, Ghislain M, Grand RL, Lambotte O, Kootstra N, Meyer L, Goujard C, Paiardini M, Albert ML, Müller-Trutwin M.

J Int AIDS Soc. 2018 Jul;21(7):e25144. doi: 10.1002/jia2.25144.

11.

A High Frequency of HIV-Specific Circulating Follicular Helper T Cells Is Associated with Preserved Memory B Cell Responses in HIV Controllers.

Claireaux M, Galperin M, Benati D, Nouël A, Mukhopadhyay M, Klingler J, de Truchis P, Zucman D, Hendou S, Boufassa F, Moog C, Lambotte O, Chakrabarti LA.

MBio. 2018 May 8;9(3). pii: e00317-18. doi: 10.1128/mBio.00317-18.

12.

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study.

Wittkop L, Arsandaux J, Trevino A, Schim van der Loeff M, Anderson J, van Sighem A, Böni J, Brun-Vezinet F, Soriano V, Boufassa F, Brockmeyer N, Calmy A, Dabis F, Jarrin I, Dorrucci M, Duque V, Fätkenheuer G, Zangerle R, Ferrer E, Porter K, Judd A, Sipsas NV, Lambotte O, Shepherd L, Leport C, Morrison C, Mussini C, Obel N, Ruelle J, Schwarze-Zander C, Sonnerborg A, Teira R, Torti C, Valadas E, Colin C, Friis-Møller N, Costagliola D, Thiebaut R, Chene G, Matheron S; COHERE in EuroCoord and ACHIeV2e Study Group.

J Antimicrob Chemother. 2017 Oct 1;72(10):2869-2878. doi: 10.1093/jac/dkx210.

13.

Detectable HIV-RNA in semen of HIV controllers.

Chaix ML, Boufassa F, Meyzer C, Leruez-Ville M, Mahjoub N, Nere ML, Genet P, Duvivier C, Lascoux-Combes C, Lambotte O, Ghosn J.

PLoS One. 2017 Aug 16;12(8):e0183376. doi: 10.1371/journal.pone.0183376. eCollection 2017.

14.

HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.

Rouers A, Klingler J, Su B, Samri A, Laumond G, Even S, Avettand-Fenoel V, Richetta C, Paul N, Boufassa F, Hocqueloux L, Mouquet H, Rouzioux C, Lambotte O, Autran B, Graff-Dubois S, Moog C, Moris A; ANRS CO21 Cohort.

EBioMedicine. 2017 Jul;21:158-169. doi: 10.1016/j.ebiom.2017.05.029. Epub 2017 May 31.

15.

A Subset of Extreme Human Immunodeficiency Virus (HIV) Controllers Is Characterized by a Small HIV Blood Reservoir and a Weak T-Cell Activation Level.

Canouï E, Lécuroux C, Avettand-Fenoël V, Gousset M, Rouzioux C, Saez-Cirion A, Meyer L, Boufassa F, Lambotte O, Noël N; and the ANRS CO21 CODEX Study Group.

Open Forum Infect Dis. 2017 Apr 3;4(2):ofx064. doi: 10.1093/ofid/ofx064. eCollection 2017 Spring.

16.

HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy.

Lachâtre M, Pasquet A, Ajana F, Soudan B, Lion G, Bocket L, Cornavin P, Senneville E, Boufassa F, Chéret A.

AIDS. 2017 Jan 28;31(3):451-453. doi: 10.1097/QAD.0000000000001348.

PMID:
28081039
17.

Preservation of Lymphopoietic Potential and Virus Suppressive Capacity by CD8+ T Cells in HIV-2-Infected Controllers.

Angin M, Wong G, Papagno L, Versmisse P, David A, Bayard C, Charmeteau-De Muylder B, Besseghir A, Thiébaut R, Boufassa F, Pancino G, Sauce D, Lambotte O, Brun-Vézinet F, Matheron S, Rowland-Jones SL, Cheynier R, Sáez-Cirión A, Appay V; ANRS CO5 IMMUNOVIR-2 Study Group.

J Immunol. 2016 Oct 1;197(7):2787-95. doi: 10.4049/jimmunol.1600693. Epub 2016 Aug 26.

18.

Strong ifitm1 Expression in CD4 T Cells in HIV Controllers Is Correlated With Immune Activation.

Canoui E, Noël N, Lécuroux C, Boufassa F, Sáez-Cirión A, Bourgeois C, Lambotte O; ANRS CO21 CODEX Study Group.

J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):e56-e59. doi: 10.1097/QAI.0000000000001166. No abstract available.

19.

Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset.

Ploquin MJ, Madec Y, Casrouge A, Huot N, Passaes C, Lécuroux C, Essat A, Boufassa F, Jacquelin B, Jochems SP, Petitjean G, Angin M, Gärtner K, Garcia-Tellez T, Noël N, Booiman T, Boeser-Nunnink BD, Roques P, Saez-Cirion A, Vaslin B, Dereudre-Bosquet N, Barré-Sinoussi F, Ghislain M, Rouzioux C, Lambotte O, Albert ML, Goujard C, Kootstra N, Meyer L, Müller-Trutwin MC.

PLoS Pathog. 2016 Aug 10;12(8):e1005774. doi: 10.1371/journal.ppat.1005774. eCollection 2016 Aug.

20.

Dendritic Cells from HIV Controllers Have Low Susceptibility to HIV-1 Infection In Vitro but High Capacity to Capture HIV-1 Particles.

Hamimi C, David A, Versmisse P, Weiss L, Bruel T, Zucman D, Appay V, Moris A, Ungeheuer MN, Lascoux-Combe C, Barré-Sinoussi F, Muller-Trutwin M, Boufassa F, Lambotte O, Pancino G, Sáez-Cirión A; ANRS CO21 CODEX cohort.

PLoS One. 2016 Aug 9;11(8):e0160251. doi: 10.1371/journal.pone.0160251. eCollection 2016.

21.

Cancers in elite controllers: appropriate follow-up is essential.

Okulicz JF, Boufassa F, Costagliola D, Ganesan A, Lambotte O.

AIDS. 2016 Jul 17;30(11):1852-5. doi: 10.1097/QAD.0000000000001154.

PMID:
27177315
22.

Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.

Noel N, Peña R, David A, Avettand-Fenoel V, Erkizia I, Jimenez E, Lecuroux C, Rouzioux C, Boufassa F, Pancino G, Venet A, Van Lint C, Martinez-Picado J, Lambotte O, Sáez-Cirión A, Prado JG.

J Virol. 2016 Jun 10;90(13):6148-6158. doi: 10.1128/JVI.00419-16. Print 2016 Jul 1.

23.

Public T cell receptors confer high-avidity CD4 responses to HIV controllers.

Benati D, Galperin M, Lambotte O, Gras S, Lim A, Mukhopadhyay M, Nouël A, Campbell KA, Lemercier B, Claireaux M, Hendou S, Lechat P, de Truchis P, Boufassa F, Rossjohn J, Delfraissy JF, Arenzana-Seisdedos F, Chakrabarti LA.

J Clin Invest. 2016 Jun 1;126(6):2093-108. doi: 10.1172/JCI83792. Epub 2016 Apr 25.

24.

Identity, Representations, and Beliefs: HIV Controllers Living on the Frontier of Good Health and Illness.

Préau M, Mora M, Laguette V, Colombani C, Boufassa F, Meyer L, Spire B, Lambotte O.

Qual Health Res. 2016 Sep;26(11):1483-94. doi: 10.1177/1049732315617739. Epub 2015 Dec 1.

PMID:
26631682
25.

Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?

Jarrin I, Pantazis N, Dalmau J, Phillips AN, Olson A, Mussini C, Boufassa F, Costagliola D, Porter K, Blanco J, Del Amo J, Martinez-Picado J; for CASCADE Collaboration in EuroCoord.

AIDS. 2015 Nov;29(17):2323-33. doi: 10.1097/QAD.0000000000000805.

26.

MELD Score Kinetics in Decompensated HIV+/HCV+ Patients: A Useful Prognostic Tool (ANRS HC EP 25 PRETHEVIC Cohort Study).

Gelu-Simeon M, Bayan T, Ostos M, Boufassa F, Teicher E, Steyaert JM, Bertucci I, Anty R, Pageaux GP, Meyer L, Duclos-Vallée JC; ANRS HC EP 25 PRETHEVIC study group.

Medicine (Baltimore). 2015 Jul;94(30):e1239. doi: 10.1097/MD.0000000000001239.

27.

Infectious complications after liver transplantation in human immunodeficiency virus-infected recipients.

Teicher E, Boufassa F, Vittecoq D, Antonini TM, Tateo MG, Coilly A, Roque-Afonso AM, Kassis-Chikhani N, Lambotte O, Ichai P, Samuel D, Duclos-Vallee JC.

Transpl Infect Dis. 2015 Oct;17(5):662-70. doi: 10.1111/tid.12422. Epub 2015 Sep 26.

PMID:
26192379
28.

Immunologic and Virologic Progression in HIV Controllers: The Role of Viral "Blips" and Immune Activation in the ANRS CO21 CODEX Study.

Noel N, Lerolle N, Lécuroux C, Goujard C, Venet A, Saez-Cirion A, Avettand-Fenoël V, Meyer L, Boufassa F, Lambotte O; ANRS C021 CODEX Study Group.

PLoS One. 2015 Jul 6;10(7):e0131922. doi: 10.1371/journal.pone.0131922. eCollection 2015.

29.

Imaging Features and Prognosis of Hepatocellular Carcinoma in Patients with Cirrhosis Who Are Coinfected with Human Immunodeficiency Virus and Hepatitis C Virus.

Lewin M, Gelu-Simeon M, Ostos M, Boufassa F, Sobesky R, Teicher E, Meyer L, Fontaine H, Salmon-Céron D, Samuel D, Seror O, Trinchet JC, Duclos-Vallée JC.

Radiology. 2015 Nov;277(2):443-53. doi: 10.1148/radiol.2015141500. Epub 2015 May 6.

PMID:
25961631
30.

Reduction of death receptor 5 expression and apoptosis of CD4+ T cells from HIV controllers.

Barblu L, Smith N, Durand S, Scott-Algara D, Boufassa F, Delfraissy JF, Cimarelli A, Lambotte O, Herbeuval JP.

Clin Immunol. 2014 Nov;155(1):17-26. doi: 10.1016/j.clim.2014.07.010. Epub 2014 Aug 7.

PMID:
25110157
31.

High eomesodermin expression among CD57+ CD8+ T cells identifies a CD8+ T cell subset associated with viral control during chronic human immunodeficiency virus infection.

Simonetta F, Hua S, Lécuroux C, Gérard S, Boufassa F, Sáez-Cirión A, Pancino G, Goujard C, Lambotte O, Venet A, Bourgeois C.

J Virol. 2014 Oct;88(20):11861-71. doi: 10.1128/JVI.02013-14. Epub 2014 Aug 6.

32.

Potential role for HIV-specific CD38-/HLA-DR+ CD8+ T cells in viral suppression and cytotoxicity in HIV controllers.

Hua S, Lécuroux C, Sáez-Cirión A, Pancino G, Girault I, Versmisse P, Boufassa F, Taulera O, Sinet M, Lambotte O, Venet A.

PLoS One. 2014 Jul 7;9(7):e101920. doi: 10.1371/journal.pone.0101920. eCollection 2014.

33.

Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration.

Boufassa F, Lechenadec J, Meyer L, Costagliola D, Hunt PW, Pereyra F, Deeks S, Pancino G, Taulera O, Lichterfeld M, Delobel P, Saez-Cirion A, Lambotte O; ANRS CO18 HIV Controllers Cohort; Cascade Collaboration in Eurocoord; SCOPE Cohort; International HIV Controllers Study.

PLoS One. 2014 Jan 17;9(1):e85516. doi: 10.1371/journal.pone.0085516. eCollection 2014.

34.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

Engsig FN, Zangerle R, Katsarou O, Dabis F, Reiss P, Gill J, Porter K, Sabin C, Riordan A, Fätkenheuer G, Gutiérrez F, Raffi F, Kirk O, Mary-Krause M, Stephan C, de Olalla PG, Guest J, Samji H, Castagna A, d'Arminio Monforte A, Skaletz-Rorowski A, Ramos J, Lapadula G, Mussini C, Force L, Meyer L, Lampe F, Boufassa F, Bucher HC, De Wit S, Burkholder GA, Teira R, Justice AC, Sterling TR, M Crane H, Gerstoft J, Grarup J, May M, Chêne G, Ingle SM, Sterne J, Obel N; Antiretroviral Therapy Cohort Collaboration (ART-CC) and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

Clin Infect Dis. 2014 May;58(9):1312-21. doi: 10.1093/cid/ciu038. Epub 2014 Jan 22.

35.

Elevated IP10 levels are associated with immune activation and low CD4⁺ T-cell counts in HIV controller patients.

Noel N, Boufassa F, Lécuroux C, Saez-Cirion A, Bourgeois C, Dunyach-Remy C, Goujard C, Rouzioux C, Meyer L, Pancino G, Venet A, Lambotte O; ANRS C021 CODEX Study Group.

AIDS. 2014 Feb 20;28(4):467-76. doi: 10.1097/QAD.0000000000000174.

PMID:
24378753
36.

Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection.

Lodi S, Fisher M, Phillips A, De Luca A, Ghosn J, Malyuta R, Zangerle R, Moreno S, Vanhems P, Boufassa F, Guiguet M, Porter K; CASCADE Collaboration in EuroCoord.

PLoS One. 2013 Nov 14;8(11):e78642. doi: 10.1371/journal.pone.0078642. eCollection 2013.

37.

Is the level of proof of the North American multicohort collaboration prospective study sufficient to conclude that incidence of invasive cervical cancer is higher in HIV-infected women?

Nazac A, Fridmann S, Boufassa F.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e163-4. doi: 10.1097/QAI.0b013e31829cb7ab. No abstract available.

PMID:
24135780
38.

Both HLA-B*57 and plasma HIV RNA levels contribute to the HIV-specific CD8+ T cell response in HIV controllers.

Lécuroux C, Sáez-Cirión A, Girault I, Versmisse P, Boufassa F, Avettand-Fenoël V, Rouzioux C, Meyer L, Pancino G, Lambotte O, Sinet M, Venet A.

J Virol. 2014 Jan;88(1):176-87. doi: 10.1128/JVI.02098-13. Epub 2013 Oct 16.

39.

High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers.

Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, Haynes BF, Delfraissy JF, Saez-Cirion A, Ferrari G.

PLoS One. 2013 Sep 23;8(9):e74855. doi: 10.1371/journal.pone.0074855. eCollection 2013.

40.

Associations between 25-hydroxyvitamin D and immunologic, metabolic, inflammatory markers in treatment-naive HIV-infected persons: the ANRS CO9 «COPANA» cohort study.

Legeai C, Vigouroux C, Souberbielle JC, Bouchaud O, Boufassa F, Bastard JP, Carlier R, Capeau J, Goujard C, Meyer L, Viard JP; ANRS-COPANA Cohort Study Group.

PLoS One. 2013 Sep 18;8(9):e74868. doi: 10.1371/journal.pone.0074868. eCollection 2013.

41.

Natural history of HIV-control since seroconversion.

Madec Y, Boufassa F, Porter K, Prins M, Sabin C, d'Arminio Monforte A, Amornkul P, Bartmeyer B, Sannes M, Venet A, Lambotte O, Meyer L; CASCADE Collaboration in Eurocoord.

AIDS. 2013 Sep 24;27(15):2451-60. doi: 10.1097/01.aids.0000431945.72365.01.

PMID:
23912979
42.

Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort.

Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, Lambotte O, Meyer L, Gougeon ML, Zitvogel L.

Oncoimmunology. 2013 Mar 1;2(3):e23472.

43.

Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study.

Sáez-Cirión A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, Potard V, Versmisse P, Melard A, Prazuck T, Descours B, Guergnon J, Viard JP, Boufassa F, Lambotte O, Goujard C, Meyer L, Costagliola D, Venet A, Pancino G, Autran B, Rouzioux C; ANRS VISCONTI Study Group.

PLoS Pathog. 2013 Mar;9(3):e1003211. doi: 10.1371/journal.ppat.1003211. Epub 2013 Mar 14.

44.

MHC-driven HIV-1 control on the long run is not systematically determined at early times post-HIV-1 infection.

Antoni G, Guergnon J, Meaudre C, Samri A, Boufassa F, Goujard C, Lambotte O, Autran B, Rouzioux C, Costagliola D, Meyer L, Theodorou I.

AIDS. 2013 Jul 17;27(11):1707-16. doi: 10.1097/QAD.0b013e328360a4bd.

PMID:
23462218
45.

Testing independence between two sequential gap times in the presence of covariates.

Pénichoux J, Moreau T, Meyer L, Boufassa F, Huber C, Latouche A.

Biom J. 2012 Nov;54(6):766-85. doi: 10.1002/bimj.201100144. Epub 2012 Oct 10.

PMID:
23047640
46.

Time to virological failure, treatment change and interruption for individuals treated within 12 months of HIV seroconversion and in chronic infection.

Zugna D, Geskus RB, De Stavola B, Rosinska M, Bartmeyer B, Boufassa F, Chaix ML, Babiker A, Porter K; CASCADE Collaboration in EuroCoord.

Antivir Ther. 2012;17(6):1039-48. doi: 10.3851/IMP2312. Epub 2012 Aug 15.

PMID:
22910338
47.

HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term.

Vingert B, Benati D, Lambotte O, de Truchis P, Slama L, Jeannin P, Galperin M, Perez-Patrigeon S, Boufassa F, Kwok WW, Lemaître F, Delfraissy JF, Thèze J, Chakrabarti LA.

J Virol. 2012 Oct;86(19):10661-74. doi: 10.1128/JVI.00056-12. Epub 2012 Jul 25.

48.

Specific anti-gp41 antibodies predict HIV-1 disease progression.

Vieillard V, Crouzet J, Boufassa F, Sennepin A, Ho Tsong Fang R, Debré P, Meyer L.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):403-5. doi: 10.1097/QAI.0b013e318264b307.

PMID:
22732471
49.

Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation.

Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, Leal M, Ruiz-Mateos E, Lambotte O, Herbeuval JP; ANRS EP36 HIV Controllers Study Group.

J Infect Dis. 2012 Sep 1;206(5):790-801. Epub 2012 Jun 12.

PMID:
22693234
50.

Blood Epstein-Barr virus DNA load and risk of progression to AIDS-related systemic B lymphoma.

Leruez-Ville M, Seng R, Morand P, Boufassa F, Boue F, Deveau C, Rouzioux C, Goujard C, Seigneurin JM, Meyer L.

HIV Med. 2012 Sep;13(8):479-87. doi: 10.1111/j.1468-1293.2012.00998.x. Epub 2012 Mar 14.

Supplemental Content

Loading ...
Support Center